NPI: 1811069685 · CLEVELAND, OH 44195 · Clinical Medical Laboratory · NPI assigned 11/15/2006
Authorized official LARAWAY, DENNIS controls 20+ related entities in our dataset. Read more
| Authorized Official | LARAWAY, DENNIS (EXECUTIVE VP CHIEF FINANCE OFFICER) |
| NPI Enumeration Date | 11/15/2006 |
Other providers sharing the same authorized official: LARAWAY, DENNIS
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 117,093 | $904K |
| 2019 | 157,640 | $975K |
| 2020 | 173,181 | $1.69M |
| 2021 | 225,932 | $3.10M |
| 2022 | 139,443 | $1.10M |
| 2023 | 109,746 | $634K |
| 2024 | 106,206 | $639K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 36,006 | 22,937 | $2.22M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 25,498 | 15,871 | $508K |
| 80053 | Comprehensive metabolic panel | 72,534 | 64,293 | $504K |
| 84443 | Thyroid stimulating hormone (TSH) | 45,049 | 42,839 | $431K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 33,635 | 32,162 | $416K |
| 80061 | Lipid panel | 46,151 | 44,158 | $368K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 67,092 | 55,933 | $321K |
| 36415 | Collection of venous blood by venipuncture | 162,261 | 110,133 | $282K |
| 87631 | 2,906 | 2,756 | $278K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 54,672 | 35,038 | $207K |
| 83036 | Hemoglobin; glycosylated (A1C) | 37,585 | 35,876 | $195K |
| 85027 | 59,611 | 42,800 | $177K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 4,840 | 4,652 | $126K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 4,867 | 4,677 | $124K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 895 | 846 | $123K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2,782 | 2,647 | $108K |
| 82607 | 13,112 | 12,448 | $102K | |
| 86480 | 2,358 | 2,285 | $92K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 3,849 | 3,774 | $90K |
| 83970 | 3,678 | 3,513 | $80K | |
| G0475 | Hiv antigen/antibody, combination assay, screening | 6,612 | 6,430 | $77K |
| 86235 | 2,502 | 1,101 | $71K | |
| 84439 | 12,914 | 12,287 | $68K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 15,421 | 14,199 | $63K |
| 82728 | 7,283 | 6,891 | $60K | |
| 83735 | 15,818 | 12,059 | $54K | |
| 86803 | 5,102 | 4,838 | $49K | |
| 87522 | Neg quan hep c or qual rna | 2,385 | 2,290 | $44K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 2,427 | 2,273 | $43K |
| 86780 | 4,265 | 4,034 | $43K | |
| 83655 | 3,946 | 3,869 | $43K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 1,760 | 1,688 | $42K |
| 80069 | 10,386 | 7,931 | $42K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 2,334 | 2,247 | $42K |
| 83550 | 7,780 | 7,421 | $41K | |
| 87077 | 9,485 | 7,467 | $41K | |
| 80050 | General health panel | 2,344 | 2,278 | $40K |
| 84153 | 3,409 | 3,231 | $38K | |
| 84403 | 2,105 | 1,974 | $36K | |
| 82043 | 9,539 | 9,194 | $36K | |
| 82570 | 11,251 | 10,606 | $35K | |
| 87340 | 4,947 | 4,740 | $35K | |
| 80076 | 6,889 | 6,091 | $35K | |
| 83540 | 8,527 | 8,073 | $34K | |
| 86140 | 10,562 | 8,116 | $33K | |
| 85610 | 20,971 | 7,881 | $33K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 628 | 395 | $33K |
| 84702 | 3,138 | 2,698 | $32K | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | 1,339 | 1,177 | $31K |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | 2,064 | 2,026 | $31K |
| 80074 | 1,791 | 1,724 | $31K | |
| 86147 | 572 | 440 | $31K | |
| 87186 | 7,231 | 5,979 | $29K | |
| 83880 | 1,471 | 1,290 | $28K | |
| 81001 | 15,245 | 14,287 | $27K | |
| 82746 | 3,362 | 3,206 | $27K | |
| 86038 | 3,008 | 2,859 | $26K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 1,210 | 1,155 | $26K |
| 84480 | 2,595 | 2,486 | $24K | |
| 84481 | 1,938 | 1,872 | $23K | |
| 84146 | 1,561 | 1,500 | $21K | |
| 84550 | 6,501 | 6,103 | $19K | |
| 83516 | 1,664 | 1,073 | $19K | |
| 87660 | 1,203 | 1,175 | $18K | |
| 84402 | 996 | 948 | $18K | |
| 82784 | 1,946 | 1,665 | $18K | |
| 85652 | 9,886 | 8,179 | $18K | |
| 87480 | 1,187 | 1,160 | $17K | |
| 87510 | 1,187 | 1,160 | $17K | |
| 87070 | 3,014 | 2,793 | $17K | |
| 86334 | 994 | 974 | $17K | |
| 82565 | 4,447 | 2,911 | $16K | |
| 86762 | 1,440 | 1,382 | $15K | |
| 86706 | 1,732 | 1,647 | $13K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 653 | 304 | $13K |
| 84100 | 4,248 | 2,884 | $12K | |
| 87493 | 821 | 783 | $12K | |
| 80164 | 1,914 | 1,696 | $12K | |
| 86255 | 893 | 697 | $12K | |
| 87505 | 197 | 187 | $12K | |
| 83001 | 812 | 773 | $12K | |
| 86003 | 547 | 206 | $11K | |
| 83690 | 2,420 | 2,315 | $11K | |
| 87205 | 3,686 | 3,439 | $11K | |
| 83721 | 1,933 | 1,849 | $10K | |
| 86592 | 2,986 | 2,876 | $10K | |
| 87536 | 178 | 167 | $10K | |
| 80197 | 1,137 | 606 | $10K | |
| 86431 | 2,159 | 2,091 | $9K | |
| 80202 | 1,089 | 477 | $9K | |
| 86704 | 1,054 | 1,020 | $9K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | 1,564 | 1,507 | $8K |
| 82150 | 1,844 | 1,763 | $8K | |
| 82550 | 1,715 | 1,322 | $8K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 200 | 184 | $8K |
| 84436 | 2,278 | 2,159 | $7K | |
| 86709 | 926 | 884 | $7K | |
| 86200 | 718 | 705 | $7K | |
| 82105 | 675 | 654 | $7K | |
| 84156 | 3,102 | 2,835 | $7K | |
| 82248 | 1,937 | 1,794 | $7K | |
| 86376 | 616 | 596 | $7K | |
| 84460 | 2,010 | 1,811 | $7K | |
| 86705 | 700 | 683 | $7K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 78 | 77 | $7K |
| 83002 | 533 | 304 | $6K | |
| 85018 | 2,763 | 2,653 | $6K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 146 | 141 | $6K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 354 | 309 | $6K |
| 82274 | 476 | 466 | $6K | |
| 86850 | 1,124 | 1,082 | $5K | |
| 82670 | 277 | 251 | $5K | |
| 82140 | 599 | 489 | $5K | |
| 85730 | 1,330 | 972 | $5K | |
| 86225 | 530 | 474 | $5K | |
| 82977 | 939 | 713 | $5K | |
| 87653 | 260 | 254 | $4K | |
| 88342 | 186 | 116 | $4K | |
| 81003 | 4,091 | 3,721 | $4K | |
| 84450 | 1,212 | 1,118 | $4K | |
| 87808 | 405 | 400 | $4K | |
| 88141 | 214 | 206 | $4K | |
| 86708 | 459 | 431 | $4K | |
| 86359 | 160 | 148 | $4K | |
| 80177 | 604 | 473 | $4K | |
| 86141 | 444 | 366 | $4K | |
| 82947 | 1,403 | 1,293 | $3K | |
| 86364 | 369 | 337 | $3K | |
| 81374 | 107 | 107 | $3K | |
| 82950 | 1,036 | 1,004 | $3K | |
| 86160 | 294 | 149 | $3K | |
| 86696 | 196 | 186 | $3K | |
| 87497 | 110 | 54 | $3K | |
| 84134 | 338 | 261 | $3K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 57 | 47 | $3K |
| 88341 | 53 | 25 | $2K | |
| 82533 | 208 | 187 | $2K | |
| 84154 | 211 | 201 | $2K | |
| 86900 | 1,069 | 1,029 | $2K | |
| 86901 | 1,068 | 1,028 | $2K | |
| 82627 | 147 | 137 | $2K | |
| 88321 | 91 | 84 | $2K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 46 | 42 | $2K |
| 82652 | 87 | 83 | $2K | |
| 86665 | 129 | 65 | $2K | |
| 85379 | 393 | 317 | $2K | |
| 84132 | 719 | 493 | $2K | |
| 84630 | 220 | 209 | $2K | |
| 86695 | 198 | 188 | $2K | |
| 80178 | 332 | 302 | $2K | |
| 86812 | 61 | 61 | $1K | |
| 88142 | 92 | 88 | $1K | |
| 82378 | 87 | 72 | $1K | |
| 86361 | 70 | 67 | $1K | |
| 86146 | 29 | 27 | $1K | |
| 84520 | 481 | 321 | $1K | |
| 99214 | Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 72 | 72 | $996.18 |
| 86800 | 77 | 76 | $953.51 | |
| 86258 | 97 | 90 | $942.72 | |
| 84165 | 135 | 118 | $936.00 | |
| 83615 | 216 | 186 | $865.19 | |
| 84155 | 396 | 375 | $852.92 | |
| 85732 | 100 | 52 | $736.66 | |
| 84425 | 49 | 42 | $674.32 | |
| 85390 | 73 | 65 | $642.70 | |
| 86765 | 67 | 66 | $641.05 | |
| 82677 | 44 | 44 | $635.28 | |
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 26 | 25 | $573.47 |
| 84144 | 39 | 34 | $570.12 | |
| 86336 | 56 | 56 | $535.95 | |
| 85597 | 38 | 36 | $535.85 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 24 | 24 | $525.45 |
| 87529 | 29 | 13 | $520.02 | |
| 82785 | 37 | 36 | $497.81 | |
| 85613 | 78 | 37 | $489.44 | |
| 85045 | 137 | 134 | $405.32 | |
| 84478 | 99 | 77 | $400.31 | |
| 86735 | 43 | 41 | $392.07 | |
| 80185 | 52 | 40 | $372.30 | |
| 80364 | 26 | 25 | $364.05 | |
| 80361 | 26 | 25 | $364.05 | |
| 82465 | 108 | 105 | $332.50 | |
| 87799 | 14 | 12 | $330.96 | |
| 86787 | 35 | 30 | $316.82 | |
| 80358 | 38 | 37 | $312.46 | |
| 86381 | 18 | 14 | $304.44 | |
| 82330 | 25 | 24 | $291.75 | |
| 80365 | 38 | 37 | $290.18 | |
| 86039 | 37 | 37 | $283.41 | |
| 83520 | 22 | 16 | $261.85 | |
| 83525 | 32 | 28 | $253.29 | |
| 85060 | 19 | 15 | $240.63 | |
| 82040 | 121 | 109 | $234.71 | |
| 80162 | 37 | 30 | $225.10 | |
| 80373 | 26 | 25 | $224.40 | |
| 85670 | 52 | 49 | $218.48 | |
| 80349 | 26 | 25 | $202.12 | |
| 80324 | 26 | 25 | $202.12 | |
| 80353 | 26 | 25 | $202.12 | |
| 80348 | 26 | 25 | $202.12 | |
| 80356 | 26 | 25 | $202.12 | |
| 80354 | 26 | 25 | $202.12 | |
| 83090 | 16 | 14 | $191.19 | |
| 84075 | 81 | 68 | $182.07 | |
| 82103 | 40 | 37 | $179.52 | |
| 86677 | 12 | 12 | $172.46 | |
| 83883 | 14 | 13 | $166.09 | |
| 87481 | 37 | 34 | $165.84 | |
| 86015 | 28 | 25 | $162.68 | |
| 82747 | 12 | 12 | $156.65 | |
| 86317 | 13 | 12 | $141.60 | |
| 87338 | 12 | 12 | $139.12 | |
| 85520 | 15 | 13 | $137.52 | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | 31 | 30 | $136.80 |
| G0452 | Molecular pathology procedure; physician interpretation and report | 19 | 15 | $136.65 |
| 86663 | 13 | 13 | $135.00 | |
| 82310 | 64 | 59 | $132.12 | |
| 82525 | 14 | 13 | $127.13 | |
| 84295 | 60 | 52 | $104.14 | |
| 82374 | 60 | 51 | $101.72 | |
| 82435 | 64 | 53 | $99.51 | |
| 82247 | 49 | 43 | $86.34 | |
| 85014 | 62 | 54 | $80.08 | |
| 87088 | 13 | 13 | $79.32 | |
| 84484 | 16 | 12 | $59.86 | |
| 86694 | 13 | 12 | $35.61 | |
| 3074F | 34 | 34 | $0.00 | |
| 3078F | 43 | 43 | $0.00 |